Clinical Research Group Sp. z o.o.

Warsaw 22 trials 10 recruiting

22 Registered trials

10 Currently recruiting

Organisation

Clinical Research Group Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100043734

Address

Ul. Sokolowska 9/u2, 01-142, Poland

Departments

-
Centrum Medyczne CRG
Clinical Research Group Sp. z o.o.
Dermatologicals
Dermatology
Dermatology and Cosmetology
N/A
NA
Nie dotyczy
not applicable
Osrodek Badan Klinicznych II i III Fazy
ul. Sokolowska 9/U-2

Clinical trials at this site (22)

Search interface

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moder… Pending

2023-508329-28-00 Atopic Dermatitis 4
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety … Recruiting

2024-520098-12-00 Cutaneous Lupus Erythematosus 4 2026-02-16
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Prurigo Nodularis 5 2024-12-12
A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 1… Recruiting

2023-508099-12-00 Dermatitis atopic 5 2024-06-20
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo… Recruiting

2025-520499-24-00 Moderate to Severe Platysma Prominence 5 2025-10-01
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting

2023-504713-76-00 Dermatitis atopic 5 2024-12-03
Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) Recruiting

2023-508879-36-00 Pruritus 5 2022-04-28
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate… Ended

2022-502188-39-00 Dermatitis atopic 4 2023-09-27
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended

2023-509425-53-00 Atopic Dermatitis 5 2015-11-09
A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder… Ended

2024-511549-20-00 Dermatitis atopic 4 2025-04-22
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-501621-20-00 Prurigo Nodularis 5 2023-10-02
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78… Ended

2022-502045-10-00 Atopic dermatitis 4 2023-08-11
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Atopic Dermatitis 5 2023-05-23
A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. Ended

2023-509746-35-00 Primary Discoid Lupus Erythematosus 4 2023-05-16
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12